SK pharmteco commits more than $200 million to US peptide and small molecule capacity
The contract manufacturer's expansion targets domestic supply as peptide drug demand strains global manufacturing.
TR
By Tom Reyes · Markets Editor
Sep 30 09:53 ETSource: Macau Business
The wire
- 01SK pharmteco announced a US investment of more than $200 million to expand small molecule and peptide manufacturing capacity.
- 02Peptide API and fill-finish capacity is the binding constraint behind supply of many approved and investigational peptide drugs, including incretins.
- 03Timelines, site details and which customers or molecules the added capacity will serve were not detailed in the announcement.
From the source
Read at macaubusiness.comSK pharmteco Announces $200-Plus Million U.S. Investment to Expand Small Molecule and Peptide Capacity
